Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) | Business Wire
sage-10k_20191231.htm
Deals In Depth: November 2020 :: Generics Bulletin
Sage Therapeutics, Shionogi ink deal for MDD treatment
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
On a Roll: FDA Calls Sage's Depression Drug a Breakthrough | BioSpace
Sage Therapeutics stock rockets 73% on hopes for breakthrough depression drug - MarketWatch
Sage advice: psychiatric drug development is tough | Evaluate
Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status - Elena Tomaselli Muensterman, Yijia Luo, Jonathon M. Parker, 2019
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
Sage rethinks SAGE-217 program after phase 3 failure | Fierce Biotech
sage-10k_20181231.htm
Sage advice: psychiatric drug development is tough | Evaluate
Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders
BioWorld
Shionogi, Sage to Partner on Developing Depression Drug in Three Asian Markets
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Defensive Strategies For Sage Therapeutics In The Aftermath Of Potential SAGE-547 Regulatory Action (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration | Business Wire
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
Discovering, developing and delivering life-changing therapies to treat rare central nervous system disorders.
SY Investing on Twitter: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE- 217 showed mean reduction of 12.6 in HAM-D total
